Jian Wang, PhD

Department of Biostatistics, Division of Discovery Science

Present Title & Affiliation

Primary Appointment

Associate Professor, Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

Associate Member, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

Associate Member, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX

Research Interests

My research mainly focuses on development and implementation of innovative statistical methods for cancer data analysis identifying disease-causing or disease-related risk factors. I am also working on development of risk models for cancer assessment and prediction.

Education & Training

Degree-Granting Education

2007	University of Colorado at Boulder, Boulder, Colorado, US, Ph.D. in Statistics
2004	University of Colorado at Boulder, Boulder, Colorado, US, M.S. in Applied Mathematics
2002	Tianjin University, Tianjin, CN, M.S. in Management Sciences
1999	Tianjin University, Tianjin, CN, B.S. in Management Sciences

Postgraduate Training

2022-2022	Continuing Education, Machine Learning and Deep Learning, Joint Statistical Meeting, Washington, DC
2020-2020	Continuing Education, Statistical Analysis of Microbiome Data with R, International Chinese Statistical Association, Houston, Texas
2016-2016	Continuing Education, Big data phenotyping: opportunities, analytic challenges, and solutions, International Genetic Epidemiology Society, Toronto
2015-2015	Continuing Education, Ingenuity Pathway Analysis Training, UT MD Anderson Cancer Center, Houston, Texas
2012-2012	Continuing Education, Next Generation Sequencing in Genetic Epidemiological Studies, International Genetic Epidemiology Society, Stevenson, Washington
2012-2012	Continuing Education, Statistical Analysis with Missing Data, Joint Statistical Meeting, San Diego, California
2012-2012	Continuing Education, Multilevel Modeling, Statistical Horizons, Philadelphia, Pennsylvania
2011-2011	Continuing Education, The Cancer Genome Atlas: An Extraordinary Enterprise, UT MD Anderson Cancer Center and the Gulf Coast Consortium for Bioinformatics, Houston, Texas
2009-2010	Continuing Education, Responsible Conduct of Research, The MD Anderson Postdoctoral Association, Houston, Texas
2009-2009	Continuing Education, Genomics in Medicine and Public Health, The University of Texas Health Science Center, Houston, Texas
2009-2009	Continuing Education, Writing and Publishing Scientific Articles, UT MD Anderson Cancer Center, Houston, Texas
2008-2008	Continuing Education, S.A.G.E. Course: Statistical Analysis for Genetic Epidemiology, UT MD Anderson Cancer Center, Houston, Texas
2007-2010	Postdoctoral Fellow, Statistical Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas
2002-2003	Continuing Education, The BURST Clear Talk Course in Speech Communication, University of Colorado at Boulder, Boulder, Texas

Experience & Service

Faculty Academic Appointments

Assistant Professor, Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2022

Instructor, Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2015

Instructor, Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2013

Other Professional Positions

Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2010

Data Analyst, Center for ReSource Conservation, Boulder, CO, 2006 - 2007

Research Assistant, University of Colorado at Boulder, Boulder, CO, 2004 - 2007

Teaching Assistant, University of Colorado at Boulder, Boulder, CO, 2002 - 2007

Research Assistant, Tianjin University, Tianjin, 1999 - 2002

Extramural Institutional Committee Activities

Member, The Institutional Review Board 4 (IRB4), The University of Texas MD Anderson Cancer Center, 2022 - Present

Member, GSBS Curriculum Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2025

Associate Member, The Institutional Review Board 4 (IRB4), The University of Texas MD Anderson Cancer Center, 2019 - 2022

Committee member, Psychosocial, Behavioral, and Health Services Research Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2021

Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2018 - 2021

Committee Member, Patient-Reported Outcomes, Survey and Population Research (PROSPR) Shared Resource advisory committee, The University of Texas MD Anderson Cancer Center, 2014 - 2015

Committee member, Psychosocial, Behavioral, and Health Services Research Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2018

Editorial Activities

Member of Editorial Board, Genetic Epidemiology, 2023 - Present

Honors & Awards

2011 - 2013	Duncan Family Institute Faculty Fellowship Award, UT MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment
2011	Travel Fellowship (German), International Genetic Epidemiology Society
2011	Travel Support to attend IISA Conference on Probability, Statistics, and Data Analysis, National Science Foundation & National Security Agency
2010	Trainee Research Day Poster Finalist, MD Anderson Cancer Center
2002	Shunchi Awards, Tianjin Shunchi Real Estate Co. Ltd
1998	Honorable Title of Excellent Student of Tianjin University, Tianjin University
1997 - 1998	First Class Scholarship of Metrobank Foundation Inc. Philippines, Metrobank Foundation Inc. Philippines
1996	Wang Kechang Scholarship, Wang Kechang Foundation
1995	Honorable Title of Pacesetter on Study of Tianjin University, Tianjin University

Professional Memberships

International Chinese Statistical Association

2020 - Present

American Statistical Association

2012 - Present

International Genetic Epidemiology Society

2011 - Present

American Society of Human Genetics

2008 - Present

Selected Presentations & Talks

Regional Presentations

2026. Bayesian Monitoring Designs with Multiple Endpoints for Phase II Clinical Trials. Invited. ASA San Antonio Chapter Virtual Seminar. San Antonio, Texas, US.
2016. Estimation of indirect effect when the mediator is a censored variable. Poster. Estimation of indirect effect when the mediator is a censored variable, TX, US.
2010. Mediating effects of smoking and chronic obstructive airway disease on the relationship between the CHRNA5-A3 genetic locus and lung cancer risk. Poster. Trainee Research Day Poster Finalist, TX, US.

National Presentations

2012. Comparison of multilevel model and the family-based association test (FBAT) for identifying SNPs associated with systolic and diastolic blood pressure using GAW18 simulated data. Poster. Comparison of multilevel model and the family-based association test (FBAT) for identifying SNPs associated with systolic and diastolic blood pressure using GAW18 simulated data. Stevenson, WA, US.

International Presentations

2026. The Bayesian Monitoring Using the Win Ratio for Phase II Trials with Multiple Time-to-Event Endpoints. Poster. 2026 Joint Statistical Meetings. Alexandria, US.
2026. A Bayesian Monitoring Approach Based on the Win Ratio for Randomized Phase II Trials with Multiple Time-to-Event Outcomes. Conference. 2026 IMS Annual Meeting. Beachwood, US.
2024. Assessing dynamic and predictive discrimination in recurrent event models using a time-dependent C-Index. Invited. 2024 ICSA Applied Statistics Symposium. Nashville, US.
2024. A Time-dependent C-index to Evaluate Dynamic and Predictive Discrimination for Recurrent Event Models. Conference. Small Area Estimation Survey & Data Science 2023-24 Conference. Lima, PE.
2024. A Bayesian Hierarchical Monitoring Design for Single-Arm Phase II Cancer Clinical Trials. Conference. 2024 Institute of Mathematical Statistics Asia Pacific Rim Meeting (IMS-APRM). Beachwood, US.
2023. Mediation analysis with a categorical exposure and a censored mediator in genetic studies. Poster. International Genetic Epidemiology Society. Nashville, US.
2022. A two-stage mixed effects model to analyze longitudinal zero-inflated microbiome count data. Poster. A two-stage mixed effects model to analyze longitudinal zero-inflated microbiome count data. Los Angeles, US.
2022. A Bayesian Hierarchical Monitoring Design for Phase II Clinical Trials: Incorporating Information on Response Duration. Invited. A Bayesian Hierarchical Monitoring Design for Phase II Clinical Trials: Incorporating Information on Response Duration. Gainesville, US.
2021. Analyzing longitudinal zero-inflated oral microbiome count data using two-stage mixed effects models. Conference. Analyzing longitudinal zero-inflated oral microbiome count data using two-stage mixed effects models. Virtual meeting, US.
2021. Analyzing longitudinal zero-inflated oral microbiome count data using two-stage mixed effects models. Poster. International Genetic Epidemiology Society. Virtual meeting, US.
2020. Mediation analysis with a censored mediator with application to a candidate gene case-control study. Poster. Mediation analysis with a censored mediator with application to a candidate gene case-control study. Virtual meeting, US.
2019. Mediation analysis in a case-control study when the mediator is a censored variable. Invited. IISA International Conference on Innovations on Data and Statistical Sciences. Mumbai, IN.
2019. Estimation of mediating effect in a mediation model with a censored mediator in a case-control study. Poster. International Genetic Epidemiology Society. Houston, US.
2019. Mediation analysis with a censored mediator in a case–control study. Conference. Mediation analysis with a censored mediator in a case–control study. Denver, US.
2018. Likelihood-ratio based approach to select X-chromosome inactivation model. Poster. International Genetic Epidemiology Society. San Diego, US.
2018. Assessing indirect effect in a mediation model with a censored mediator. Conference. American Statistical Association Joint Statistical Meetings. Vancouver, CA.
2018. Estimation of mediating effect in a mediation model with a censored mediator. Invited. IISA International Conference on Statistics. Gainesville, US.
2017. A novel approach to analyze the mediation model when the mediator is a censored variable. Poster. A novel approach to analyze the mediation model when the mediator is a censored variable. Orlando, US.
2017. Estimating indirect effect when the mediator is a censored variable in a mediation model. Invited. International Genetic Epidemiology Society. Cambridge, GB.
2016. A unified X-chromosome genetic association test accounting for different XCI processes. Conference. A unified X-chromosome genetic association test accounting for different XCI processes. Atlanta, US.
2015. Empirical estimation of sequencing error rates using smoothing splines. Poster. 24th Annual Meeting of International Genetic Epidemiology Society. Baltimore, US.
2014. A unified analysis approach for X-chromosome that accounts for random, skewed and escaping of X-chromosome inactivation. Poster. A unified analysis approach for X-chromosome that accounts for random, skewed and escaping of X-chromosome inactivation. San Diego, US.
2013. X-chromosome genetic association test accounting for X-inactivation, skewed X-inactivation, and escaping of X-inactivation. Poster. 22nd Annual Meeting of International Genetic Epidemiology Society. Chicago, US.
2012. Multiple mediation analysis in case-control studies: application to detecting joint mediating effects of smoking and chronic obstructive pulmonary disease on the association between CHRNA5-A3 genetic locus and lung cancer risk. Poster. Multiple mediation analysis in case-control studies: application to detecting joint mediating effects of smoking and chronic obstructive pulmonary disease on the association between CHRNA5-A3 genetic locus and lung cancer risk. San Francisco, US.
2012. Method to analyze multiple mediators in case-control studies with application to detecting mediating effects of smoking and chronic obstructive pulmonary disease on the association between CHRNA5-A3 genetic locus and lung cancer risk. Poster. 21st Annual Meeting of International Genetic Epidemiology. Stevenson, US.
2011. Selection of top SNPs for genome-wide association study using p values and magnitude of odds ratios. Poster. American Society of Human Genetics. Montreal, CA.
2011. Selection of top SNPs for genome-wide association study using p values and magnitude of odds ratios. Poster. International Genetic Epidemiology Society. Heidelberg, DE.
2011. Estimation of odds ratio of genetic variants for secondary phenotype associated with primary disease. Invited. Estimation of odds ratio of genetic variants for secondary phenotype associated with primary disease. Raleigh, US.
2010. Estimation of odds ratios of genetic variants for the secondary phenotypes associated with primary diseases. Invited. International Genetic Epidemiology Society. Boston, US.
2009. Mediating effects of smoking and chronic obstructive airway disease on the relationship between the CHRNA5-A3 genetic locus and lung cancer risk. Poster. Mediating effects of smoking and chronic obstructive airway disease on the relationship between the CHRNA5-A3 genetic locus and lung cancer risk. Honolulu, US.
2008. A test for genetic association that incorporates information from population genetics. Poster. A test for genetic association that incorporates information from population genetics. Philadelphia, US.

Formal Peers

2021. A Bayesian hierarchical monitoring design for phase II clinical trials: incorporating information on response duration. Invited. Houston, TX, US.
2021. Oral microbiome and oral mucositis in patients with squamous cell carcinoma of the head and neck. Invited. Houston, TX, US.
2019. Estimation of mediating effect in a mediation model with a censored mediator. Invited. Houston, TX, US.
2014. A multiple mediation model for genome-wide association studies: application to CHRNA5-A3 gene locus, smoking behavior, COPD, and lung cancer. Invited. Houston, TX, US.

Less

Grant & Contract Support

Date:	2026 - 2031
Title:	DDIAS as a hub for endothelial protection against radiation injury
Funding Source:	NIH
Role:	Co-I
ID:	#TBA

Date:	2026 - 2031
Title:	HEALTH4Families: A weight management and health behavior intervention for families with genetic predisposition to cancer
Funding Source:	NIH
Role:	Co-I
ID:	#TBA

Date:	2026 - 2030
Title:	HEALTH4Families: A weight management and health behavior intervention for families with genetic predisposition to cancer
Funding Source:	CPRIT
Role:	Co-I
ID:	#TBA

Date:	2026 - 2029
Title:	Restoring the glioblastoma to cervical lymph node immune circuit to jolt anti-tumor immunity back to life
Funding Source:	CPRIT
Role:	Co-I
ID:	#TBA

Date:	2026 - 2029
Title:	Manipulating Macrophages to Improve Targeted Therapy in Melanoma
Funding Source:	CPRIT
Role:	Co-I
ID:	#TBA

Date:	2026 - 2029
Title:	DKK1 as a Clinically Actionable Target in Triple- Negative Breast Cancer
Funding Source:	CPRIT
Role:	Co-I
ID:	#TBA

Date:	2026 - 2030
Title:	Mechanisms of improved vascular function by exercise
Funding Source:	NIH
Role:	Co-I
ID:	#TBA

Date:	2026 - 2028
Title:	DKK1 as a Key Driver and Therapeutic Target in Tumorigenesis and Stemness of Aggressive Breast Cancer
Funding Source:	AMERICAN CANCER SOCIETY, NATIONAL
Role:	Co-I
ID:	#TBA

Date:	2026 - 2029
Title:	Predicting and Preventing Chemotherapy-Induced Peripheral Neuropathy Through Gut Microbiota Signatures
Funding Source:	UT Health at the Texas Medical Center
Role:	Co-I
ID:	RP260740

Date:	2026 - 2029
Title:	Predicting and Preventing Chemotherapy-Induced Peripheral Neuropathy Through Gut Microbiota Signatures
Funding Source:	CPRIT
Role:	Co-I
ID:	#TBA

Date:	2026 - 2029
Title:	Mechanistic insights into DKK1-mediated tumor growth and metastasis in aggressive breast cancers
Funding Source:	US Department of Defense
Role:	Co-I
ID:	BC251460

Date:	2026 - 2028
Title:	The role of tertiary lymphoid structures in brain tumor therapy with oncolytic adenoviruses
Funding Source:	NIH
Role:	Co-I
ID:	#TBA

Date:	2026 - 2031
Title:	AYA LASSO: A statewide platform to assess and improve long-term health outcomes in AYA cancer survivors
Funding Source:	CPRIT
Role:	Multiple Principal Investigator
ID:	RP260740

Date:	2026 - 2031
Title:	A Novel MELK-DKK1 Axis Regulates Cancer Stemness in Aggressive Breast Cancers
Funding Source:	NIH
Role:	Co-I
ID:	#TBA

Date:	2026 - 2031
Title:	NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
Funding Source:	NIH
Role:	Co-I
ID:	#TBA

Date:	2026 - 2029
Title:	Scrambler Therapy for Painful Diabetic Peripheral Neuropathy: A Randomized, Sham-Controlled Feasibility T
Funding Source:	NIH
Role:	Co-I
ID:	#TBA

Date:	2025 - 2028
Title:	Impact of Patient Fitness and Biological Aging on Outcomes for Multiple Myeloma treated with BCMA T-Cell Redirectio
Funding Source:	CPRIT
Role:	Co-I
ID:	RP260128

Date:	2025 - 2030
Title:	Fitness and Aging in Multiple Myeloma: Impact on BCMA T-Cell Redirection Therapy Outcomes
Funding Source:	NIH
Role:	Co-I
ID:	#TBA

Date:	2025 - 2030
Title:	Dual Role of PEA-15 (phosphoprotein enriched in astrocytes) in Aggressive Breast Cancers
Funding Source:	NIH
Role:	Co-I
ID:	#TBA

Date:	2025 - 2030
Title:	Mechanisms of improved vascular function by exercise
Funding Source:	NIH
Role:	PI
ID:	#TBA

Date:	2025 - 2030
Title:	Improving genetic testing completion rates for minority and underserved patients through the CARE multi-level program
Funding Source:	NIH
Role:	Co-I
ID:	#TBA

Date:	2025 - 2030
Title:	Investigating the feasibility of a novel exercise and energy conservation intervention for fatigued young adult brain tumor survivors
Funding Source:	NIH
Role:	Co-I
ID:	#TBA

Date:	2025 - 2027
Title:	Tele-PancFit: Tele-exercise for patients with resectable pancreatic cancer on tumor microenvironment and clinical outcomes
Funding Source:	NCI
Role:	Co-I
ID:	#TBA

Date:	2025 - 2030
Title:	Role of targeting ATPases BRG1/BRM in therapy of AML
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA291918-01A1

Date:	2025 - 2025
Title:	Online delivery of real-world self-management coping strategies to improve adherence to tucatinib in combination with trastuzumab and capecitabine
Funding Source:	Pfizer Inc
Role:	Co-I
ID:	#TBA

Date:	2025 - 2030
Title:	Biomarkers for depression and anxiety in chronic pain: A translational rodent-human study
Funding Source:	University of Alabama - Birmingham
Role:	Biostatistician
ID:	#TBA

Date:	2025 - 2030
Title:	Innate Immune Remodeling of the Glioblastoma Myeloid Stroma
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	PA-20-185

Date:	2025 - 2030
Title:	Prospective Study of Cannabis Use in Patients with Cancer: Benefits, Harms, and Drug Interactions
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2025 - 2030
Title:	Burst versus tonic spinal cord stimulation for chemotherapy induced peripheral neuropathy
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	#TBA

Date:	2025 - 2028
Title:	Targeting of Cancer Stem cells by inhibition MELK in Aggressive Breast Cancers
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP220298

Date:	2025 - 2029
Title:	Cancer-Related Fatigue and its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-Exercise Intervention
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP250190

Date:	2025 - 2029
Title:	Studies to Characterize and overcome Menin inhibitor resistance in pediatric AML with MLL rearrangement
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP250388

Date:	2025 - 2028
Title:	RP250103 Benefits and Harms of Cannabis Use in Texas Residents with Cancer Undergoing First-Line Immunotherapy: A Multi-Site Prospective Observational Study
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP250103

Date:	2025 - 2028
Title:	Immune checkpoint cytoreduction: undermining cancer from within
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	#TBA

Date:	2025 - 2029
Title:	Tele-PancFit: Tele-exercise for patients with resectable pancreatic cancer on tumor microenvironment and clinical outcomes
Funding Source:	CANCER PREVENTION RESEARCH INST OF TX
Role:	Co-I
ID:	#TBA

Date:	2025 - 2030
Title:	Improving efficacy and overcoming resistance to Menin inhibitor-based therapy in AML
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2025 - 2026
Title:	Exercise may impair delivery of nab-paclitaxel to PDAC
Funding Source:	American Cancer Society (ACS)
Role:	Biostatistician
ID:	#TBA

Date:	2024 - 2029
Title:	RISE-YA: a novel intervention for young adult brain tumor survivors with cancer related fatigue
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2024 - 2027
Title:	Testing Feasibility of a Tele-Exercise Intervention on Cognitive Function and Gut Microbiome in Young Adult Brain Tumor Survivors
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2024 - 2026
Title:	Tele-PancFit: Impact of video supervised exercise for patients with resectable pancreatic cancer on tumor immune cell infiltration
Funding Source:	NIH/NCI
Role:	Co-I
ID:	GRANT14066400

Date:	2024 - 2026
Title:	A novel immune modulator CD200 antibody targeting leukemic stem cell (LSC) in acute myeloid leukemia (AML)
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R21CA288670-01A1

Date:	2024 - 2026
Title:	Deciphering the role of MELK in tumor stemness and immune microenvironment in models of aggressive breast cancer
Funding Source:	American Cancer Society, National
Role:	Co-I
ID:	#TBA

Date:	2024 - 2029
Title:	Biology and efficacy of Menin Inhibitors in AML therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	PA-20-185

Date:	2024 - 2029
Title:	Scrambler Therapy: An Innovative Approach to CIPN Management
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2024 - 2029
Title:	A novel MELK-DKK1 pathway regulates stemness in Aggressive Breast Cancers
Funding Source:	NIH/NCI
Role:	Co-I
ID:	GRANT14056178

Date:	2024 - 2029
Title:	Role of disparities and aging biomarkers in accelerated cardiac aging among adolescent and young adult cancer survivors
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA285599

Date:	2024 - 2029
Title:	Role of targeting ATPases BRG1/BRM in therapy of AML
Funding Source:	NATIONAL CANCER INSTITUTE
Role:	Co-I
ID:	GRANT13985617

Date:	2024 - 2029
Title:	Improving efficacy of Menin Inhibitor-based therapy of AML
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2024 - 2029
Title:	Prospective Study of Cannabis Use in Patients with Cancer: Benefits, Harms, and Drug Interactions
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA292235-01

Date:	2024 - 2029
Title:	Improvement of PDAC vascular function by exercise
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	#TBA

Date:	2024 - 2029
Title:	Systematic approach for managing secondary findings in clinical oncology practice
Funding Source:	NIH/NCI
Role:	Co-I
ID:	PAR-21-035

Date:	2024 - 2029
Title:	Patient-reported symptom burden and functioning impairment during survivorship post Chimeric Antigen Receptor T-cell Therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA291632

Date:	2024 - 2027
Title:	Preoperative exercise for patients with pancreatic cancer- optimizing the exercise dose based on physical function, patient reported outcomes, and tumor biology
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	#TBA

Date:	2024 - 2029
Title:	Scrambler Therapy: An Innovative Approach to CIPN Management
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2024 - 2029
Title:	Design and testing of personalized Therapy for AML based on tobacco use
Funding Source:	NIH/NCI
Role:	Co-I
ID:	PA-20-185

Date:	2024 - 2028
Title:	Targeting of Cancer Stem cells by inhibiting MELK in Aggressive Breast Cancers
Funding Source:	American Cancer Society, National
Role:	Co-I
ID:	#TBA

Date:	2024 - 2025
Title:	Role of MELK as a novel therapeutic target in aggressive breast cancers
Funding Source:	ELSA U PARDEE FOUNDATION
Role:	Co-I
ID:	#TBA

Date:	2024 - 2029
Title:	Tele-PancFit: A multi-site trial of remotely supervised, home-based exercise prehabilitation during pancreatic cancer chemotherapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	GRANT13928782

Date:	2024 - 2029
Title:	MELK as a Driver of Progression and Metastasis in Aggressive Breast Cancers
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2024 - 2029
Title:	attIL12 modified TIL transfer for enhanced tumor infiltration in autologous liposarcoma PDX tumors
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	PA-20-185

Date:	2024 - 2026
Title:	A novel immune modulator CD200 antibody targeting leukemic stem cell (LSC) in acute myeloid leukemia (AML)
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R21 CA288670-01

Date:	2024 - 2028
Title:	Studies to Characterize and overcome Menin inhibitor resistance in pediatric AML with MLL rearrangement
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP240180

Date:	2024 - 2028
Title:	Cancer-related fatigue and its biomarkers in adolescent and young adult brain tumor survivors: effects of a tele-exercise intervention
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	#TBA

Date:	2024 - 2027
Title:	Multifaceted roles of AXL in shaping tumor immune microenvironment
Funding Source:	UNIV OF HOUSTON Subaward-Subcontract
Role:	Co-I
ID:	#TBA

Date:	2023 - 2028
Title:	Virtual exercise intervention on gut microbiome and cognitive impairment in adolescent and young adult brain tumor survivors
Funding Source:	Emory University
Role:	Co-I
ID:	#TBA

Date:	2023 - 2027
Title:	Identification of gut microbiome signatures as biomarkers of response, recurrence, and resistance to novel chemotherapies, immunotherapies, and molecularly targeted therapies in children and adolesce
Funding Source:	V Foundation
Role:	Co-I
ID:	#TBA

Date:	2023 - 2024
Title:	From cancer associations to altered immunity in the pathogenesis of Parkinson’s disease (Additional year - Year 4)
Funding Source:	Harvard Medical School Subaward-Subcontract
Role:	Collaborator
ID:	ASAP-024401

Date:	2023 - 2028
Title:	Improving efficacy of Menin Inhibitor-based therapy of AML
Funding Source:	NIH/NCI
Role:	Co-I
ID:	FP00018561

Date:	2023 - 2028
Title:	Prospective Cohort Study of Cannabis-based Product Use in Patients with Cancer: Comprehensive Examination of Use Patterns, Benefits, Harms, Interaction with Other Medications, and Patient Outcomes
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1U01CA286817-01

Date:	2023 - 2024
Title:	From cancer associations to altered immunity in the pathogenesis of Parkinson’s disease - Year 4
Funding Source:	Harvard Medical School Subaward-Subcontract
Role:	Collaborator
ID:	237603/AWD0005569

Date:	2023 - 2030
Title:	Elucidating and targeting epigenetic mechanisms and dysregulated transcriptome-based vulnerabilities to eradicate minimal residual disease Acute Myeloid Leukemia
Funding Source:	NIH/NCI
Role:	Co-I
ID:	GRANT13751882

Date:	2023 - 2028
Title:	MELK as a Driver of Progression and Metastasis in Aggressive Breast Cancers
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA282054-01

Date:	2023 - 2028
Title:	Development of mutant PEA-15 as a novel therapeutic for triple-negative breast cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA282511-01

Date:	2023 - 2028
Title:	Improvement of PDAC vascular function by exercise
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA282033-01

Date:	2023 - 2028
Title:	Blocking DNA damage response induction of "don’t eat me" signals converts local radiotherapy into systemic immunotherapy
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1-R01-CA276571-01-A1

Date:	2023 - 2028
Title:	Developing novel Menin Inhibitor-based combinations for therapy of AML with MLL1 rearrangement or mutant NPM1
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA276036-01A1

Date:	2023 - 2026
Title:	Effective non-pharmacologic treatment of Painful Diabetic Peripheral Neuropathy
Funding Source:	NIH/NCI
Role:	Research Programmer
ID:	1 R01 DK135263-01A1

Date:	2023 - 2024
Title:	Fibrinogen supplementation for acquired fibrinogen deficiency in acute leukemia: A single-center retrospective study
Funding Source:	Octapharma USA, Inc
Role:	Statistician Analysist
ID:	FP00018000

Date:	2023 - 2028
Title:	Revealing the unique role of PD-L2 in modulating human T cell immune responses
Funding Source:	NIH/NIAID
Role:	Collaborator
ID:	1R01AI175275-01

Date:	2023 - 2028
Title:	Biology and efficacy of Menin Inhibitors in AML therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA272870-01A1

Date:	2023 - 2028
Title:	Tele-PancFit: A multi-site trial of remotely supervised, home-based exercise prehabilitation during pancreatic cancer chemotherapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA279856-01

Date:	2023 - 2028
Title:	Systematic approach for managing secondary findings of genomic profiling in clinical practice
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01HG013018-01

Date:	2023 - 2026
Title:	Blocking DNA damage response induction of “don’t eat me” signals converts local radiotherapy into systemic immunotherapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP230135

Date:	2023 - 2026
Title:	PEA-15 Gene Therapy for Aggressive Breast Cancers
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	#TBA

Date:	2023 - 2027
Title:	The Role of MELK in Stromal Reorganization of Aggressive Breast Cancers
Funding Source:	USA Medical Research Acq Activity
Role:	Co-I
ID:	BC220287

Date:	2023 - 2026
Title:	Targeting of Cancer Stem cells by inhibition of MELK in Aggressive Breast Cancers
Funding Source:	American Cancer Society (ACS)
Role:	Collaborator
ID:	#TBA

Date:	2023 - 2026
Title:	Multifaceted roles of AXL in shaping tumor immune microenvironment
Funding Source:	Subaward-Subcontract via UNIV OF HOUSTON
Role:	Collaborator
ID:	#TBA

Date:	2022 - 2024
Title:	Incorporating implications of incidental germline findings discovered during tumor genomic profiling into clinical practice
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R21CA277292-01

Date:	2022 - 2027
Title:	Statistical Methods for Integration of Multiple Data Sources toward Precision Cancer Medicine
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA269696-01A1

Date:	2022 - 2027
Title:	Elucidating how cigarette smoking promotes AML progression and treatment resistance
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA271610-01A1

Date:	2022 - 2027
Title:	Blocking DNA damage response induction of "don’t eat me" signals converts local radiotherapy into systemic immunotherapy
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1R01CA276571-01

Date:	2022 - 2027
Title:	Exercise regulation of vasculature as an adjuvant to therapy for melanoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA266525-01A1

Date:	2022 - 2027
Title:	Biology and efficacy of Menin Inhibitors in AML therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA272870-01

Date:	2022 - 2027
Title:	Targeting the PEA-15/IL-8 pathway for triple-negative breast cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R01 CA272849-01

Date:	2022 - 2023
Title:	Role of MELK as a novel therapeutic target in aggressive breast cancers
Funding Source:	Elsa U Pardee Foundation
Role:	Co-I
ID:	#TBA

Date:	2022 - 2024
Title:	Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults with Cancer: A two arm pilot study
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R21CA256136-01A1

Date:	2022 - 2025
Title:	Multifaceted roles of AXL in shaping tumor immune microenvironment
Funding Source:	UNIV OF HOUSTON
Role:	Collaborator
ID:	#TBA

Date:	2021 - 2024
Title:	BC210692: MELK as a Driver of Inflammatory Breast Cancer Progression and Metastasis
Funding Source:	US Department of Defense
Role:	Co-I
ID:	BC210692

Date:	2021 - 2025
Title:	Novel combination therapy for AML expressing mutant RUNX1
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5R01CA262636-02

Date:	2021 - 2025
Title:	Novel targeted therapies of AML stem-progenitor cells
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA266349-01

Date:	2021 - 2024
Title:	CA201140: Leveraging electronic activity monitoring to assess performance status in Adolescent and Young Adult (AYA) cancer patients
Funding Source:	US Department of Defense
Role:	Co-I
ID:	CA201140

Date:	2021 - 2024
Title:	Exercise-induced C16-ceramide as adjuvant therapy for patients with Ewing sarcoma
Funding Source:	US Department of Defense
Role:	Statistician
ID:	CA200332

Date:	2021 - 2024
Title:	CA201074: NKG2D Ligand-Inducing T cell therapy for treating highly malignant osteosarcoma tumors
Funding Source:	US Department of Defense
Role:	Biostatistician
ID:	CA201074

Date:	2021 - 2026
Title:	Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse
Funding Source:	NIH/NINDS
Role:	Biostatistician
ID:	5R01NS122857-02

Date:	2021 - 2022
Title:	Health-related quality of life in long term immune checkpoint inhibitor survivors
Funding Source:	ECOG -ACRIN Medical Research Foundation
Role:	Co-I
ID:	#TBA

Date:	2021 - 2025
Title:	Incorporating implications of incidental germline findings discovered during tumor genomic profiling into clinical practice
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA264169-01

Date:	2021 - 2025
Title:	Incorporating implications of incidental germline findings discovered during tumor genomic profiling into clinical practice
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA264169-01A1

Date:	2021 - 2022
Title:	Cross-sectional Study of the Association Between Discrimination, Trust and Pain Outcomes Among Black Women with Early Stage Breast Cancer After Mastectomy
Funding Source:	Conquer Cancer Foundation
Role:	Co-I
ID:	#TBA

Date:	2021 - 2026
Title:	Biology and novel therapy of Richter Transformation Diffuse Large B Cell Lymphoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA261729-01

Date:	2021 - 2024
Title:	RA200247: Melk Inhibition: A novel therapeutic strategy to treat inflammatory Breast Cancer
Funding Source:	US Department of Defense
Role:	Co-I
ID:	RA200247

Date:	2021 - 2023
Title:	Addressing Financial Toxicity in Young Adult Cancer Survivors by Engaging Stakeholders in the Development of a Coping-Based Intervention
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	1R21CA261864-01

Date:	2021 - 2022
Title:	NO TITLE PROVIDED
Funding Source:	NIH
Role:	PI

Date:	2021 - 2022
Title:	Targeted inhibition of polo-like kinase 1 promotes therapeutic efficacy in pediatric high-risk ALL
Funding Source:	Childrens Leukemia Research Assoc INC
Role:	Co-I
ID:	#TBA

Date:	2021 - 2026
Title:	Biology and novel therapy of Richter Transformation Diffuse Large B Cell Lymphoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2021 - 2026
Title:	Study of PRC2-independent mechanisms in DIPG
Funding Source:	NIH/NINDS
Role:	Co-I
ID:	1R01NS121326-01

Date:	2021 - 2026
Title:	Tumor heterogeneity and DIPG therapeutics development
Funding Source:	NIH/NINDS
Role:	Co-I
ID:	1R01NS121162-01

Date:	2021 - 2023
Title:	Efficacy of Dronabinol as a treatment for chemotherapy-induced peripheral neuropathy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R03CA259651-01

Date:	2021 - 2027
Title:	Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease Outcomes
Funding Source:	NIH/NCI subaward via Baylor College of Medicine
Role:	Co-I
ID:	5R01CA256977-02

Date:	2020 - 2025
Title:	Biology and novel therapy of AML expressing somatic or germline mutant RUNX1
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5R01CA255721-03

Date:	2020 - 2022
Title:	Clonality and mechanisms of resistance to targeted therapy in osteosarcoma
Funding Source:	Hyundai Hope on Wheels
Role:	Biostatistician
ID:	#TBA

Date:	2020 - 2026
Title:	Peer-Based Approaches to Enhance Physical Activity in Dyads of Inactive Women
Funding Source:	NIH/NHLBI
Role:	Co-I
ID:	5R01HL155310-03

Date:	2020 - 2023
Title:	From cancer associations to altered immunity in the pathogenesis of Parkinson’s disease
Funding Source:	Aligning Science Across Parkinson’s (ASAP) subaward via Massachusetts General Hospital
Role:	Collaborator
ID:	ASAP-0312

Date:	2020 - 2025
Title:	Sphingolipid signaling in the tumor response to exercise
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA255749-01

Date:	2020 - 2025
Title:	Targeting Type I Arginine Methyltransferases to Overcome Cancer Immune Resistance
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA255551-01

Date:	2020 - 2023
Title:	Intraperitoneal Immune Checkpoint Blockade as a novel approach to induce anti-tumor immunity and asses dynamic changes in the peritoneal microenvironment
Funding Source:	US Department of Defense
Role:	Co-I
ID:	#TBA

Date:	2020 - 2022
Title:	Chemotherapy Induced Painful Peripheral Neuropathy: A Novel Treatment
Funding Source:	University of Texas Medical Branch
Role:	Co-I
ID:	#TBA

Date:	2020 - 2022
Title:	A novel treatment for chemotherapy induced painful peripheral neuropathy
Funding Source:	University of Texas Medical Branch
Role:	Co-I
ID:	#TBA

Date:	2020 - 2020
Title:	Optimizing Patient-centered Survivorship Outcomes in Young-Onset Colorectal Cancer
Funding Source:	Colorectal Cancer Alliance
Role:	Collaborator
ID:	#TBA

Date:	2020 - 2026
Title:	Reducing Disparities in the Risk of Hepatocellular Cancer
Funding Source:	Cancer Prevention Institute of Texas (CPRIT) subaward via Baylor College of Medicine
Role:	Collaborator
ID:	RP200633

Date:	2020 - 2025
Title:	Breaking down tumor immune privilege through targeted hypoxia reduction
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	5R01CA251816-03

Date:	2020 - 2025
Title:	Translational Pain Research Training Program
Funding Source:	NIH/NCI
Role:	Statistician
ID:	1T32NS115654-01

Date:	2020 - 2025
Title:	A peer-based approach to enhance physical activity in inactive women
Funding Source:	American Cancer Society (ACS)
Role:	Biostatistician
ID:	ID134608

Date:	2020 - 2024
Title:	Multifaceted Roles of AXL in shaping tumor immune microenvironment
Funding Source:	University of Houston
Role:	Co-I
ID:	#TBA

Date:	2020 - 2023
Title:	Intraperitoneal immune checkpoint blockade as a novel approach to reverse the immunosuppressive peritoneal tumor microenvironment in patients with carcinomatosis due to gynecologic cancers
Funding Source:	Conquer Cancer Foundation
Role:	Statistical Analyst
ID:	#TBA

Date:	2020 - 2021
Title:	Dynamics of Tumor Volume and Immune Response during Immune Checkpoint Blockade +/- Local Consolidation Therapy for Stage IV Non-Small Cell Lung Cancer
Funding Source:	Conquer Cancer Foundation
Role:	Co-I
ID:	#TBA

Date:	2020 - 2025
Title:	Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5R01CA233457-03

Date:	2020 - 2025
Title:	Peer-based Approaches to Enhance Social Support for Physical Activity in Dyads of Inactive Women
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01HL148073-01A1

Date:	2020 - 2025
Title:	Therapy for AML expressing somatic or germline mutant RUNX1
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA240378-01A1

Date:	2020 - 2023
Title:	BC191321: Drug Discovery of Potent Inhibitors of Maternal Embryonic Leucine Zipper Kinase as Targeted therapies for Triple Negative Breast Cancer
Funding Source:	US Department of Defense
Role:	Co-I
ID:	#TBA

Date:	2020 - 2024
Title:	Doxorubicin‐induced Cardiotoxicity: Defining Blood and Echocardiogram Biomarkers in a mouse model and AYA Sarcoma Patients for Evaluating Exercise Interventions
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP200381

Date:	2020 - 2023
Title:	High-sensitivity 19F MRI for clinically translatable imaging of adoptive NK cell brain tumor therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP200223

Date:	2020 - 2022
Title:	Mutant PEA-15 as a novel therapeutic strategy for Triple-Negative breast Cancer
Funding Source:	Emerson Collective
Role:	Collaborator
ID:	#TBA

Date:	2020 - 2024
Title:	Proteo-genomics of resistance to targeted therapy in osteosarcoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	#TBA

Date:	2020 - 2023
Title:	RP200086: Targeting Triple-Negative Breast Cancer stem-like cells through selective inhibitors of MELK
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	#TBA

Date:	2020 - 2020
Title:	Advancing Potent Inhibitors of Maternal Embryonic Leucine Zipper Kinase into Targeted Therapies for TNBC
Funding Source:	Elsa U Pardee Foundation
Role:	Co-I
ID:	#TBA

Date:	2020 - 2022
Title:	A Novel Dendritic Cell Vaccine and anti-PD1 for Osteosarcoma Therapy
Funding Source:	Pediatric Cancer Research Foundation
Role:	Co-I
ID:	#TBA

Date:	2019 - 2024
Title:	Pathophysiology of immune-related adverse events from immune checkpoint inhibitor therapy
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1U01CA247544-01

Date:	2019 - 2021
Title:	Controlled high-fiber dietary intervention to modulate gut microbiome in melanoma patients receiving immunotherapy
Funding Source:	Mark Foundation for Cancer Research
Role:	Statistician
ID:	AWD00004538

Date:	2019 - 2024
Title:	Novel analysis of association between microbiome and treatment infection in AML
Funding Source:	NIH/NIAD subaward via Columbia University
Role:	Co-I
ID:	5R01AI143886-04

Date:	2019 - 2024
Title:	The proteo-genomics of resistance to targeted therapy in osteosarcoma
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	FP00007480

Date:	2019 - 2024
Title:	Study of Arrestins in Brain Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01NS113909-01

Date:	2019 - 2024
Title:	Novel analysis of association between microbiome and treatment infection in AML
Funding Source:	Columbia University
Role:	PD/PI
ID:	FP00005520_Res1

Date:	2019 - 2024
Title:	Development of mutant PEA-15 as a therapeutic strategy for triple-negative breast cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA244259-01

Date:	2019 - 2023
Title:	CA190780: Study of ONC201 in Diffuse Intrinsic Pontine Glioma
Funding Source:	US Department of Defense
Role:	Co-I
ID:	FP00008981

Date:	2019 - 2022
Title:	BC181326: Drug Discovery of Potent Inhibitors of Maternal Embryonic Leucine Zipper Kinase as Targeted therapies for Triple Negative Breast Cancer
Funding Source:	US Department of Defense
Role:	Co-I
ID:	FP00006927

Date:	2019 - 2021
Title:	Immunotherapy biomarkers and targets in the peritoneal tumor microenvironment
Funding Source:	FOUNDATION FOR THE NATL INST OF HEALTH
Role:	Collaborator
ID:	FP00007248

Date:	2019 - 2021
Title:	The effects of the cutaneous microbiome in immune-related adverse event in the skin of patients receiving checkpoint inhibitor therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	FP00007457

Date:	2019 - 2026
Title:	Cancer Center Support Grant (CORE) - Biostatistics Resource Group (BRG)
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	5P30 CA016672 47

Date:	2019 - 2024
Title:	The Interplay of Tumor Metabolic and Oncogenic Pathways in Immune Resistance
Funding Source:	University of Houston
Role:	Co-I
ID:	FP00006596

Date:	2019 - 2024
Title:	Targeting MELK in triple negative breast cancer metastasis
Funding Source:	NIH/NCI (subaward University of Texas Austin)
Role:	Co-I
ID:	FP00006640

Date:	2019 - 2024
Title:	Skin Micro-Environmental Influences on Melanoma Driver Mutagenesis
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01ES030732-01

Date:	2019 - 2024
Title:	Doxorubicin-induced Cardiotoxicity: Defining Early Blood and Echocardiographic Biomarkers in a mouse model and AYA Sarcoma Patients for Evaluating Exercise Interventions
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01HL147962-01

Date:	2019 - 2024
Title:	Peer-based Approaches to Enhance Social Support for Physical Activity in Dyads of Inactive Women
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01HL148073-01

Date:	2019 - 2024
Title:	High sensitivity 19F MRI for clinically translatable imaging of adoptive NK cell brain tumor therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA240421-01

Date:	2019 - 2024
Title:	Peer-based approaches to enhance physical activity in inactive women
Funding Source:	American Cancer Society (ACS)
Role:	Biostatistician
ID:	FP00006709

Date:	2019 - 2021
Title:	Using Connectomics and Machine Learning to Predict Survival in Diffuse Glioma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R03CA241862-01

Date:	2019 - 2020
Title:	Targeting Polo-like kinase 1(PLK) as a common kinase-driver in Ph-like ALL
Funding Source:	Cure Childhood Cancer
Role:	Biostatistician
ID:	FP00007904

Date:	2019 - 2024
Title:	Murine glioblastomas lacking Quaking, p53 and PTEN (QPP) model the key genetic and immunologic features of human disease
Funding Source:	NIH Division of Intramural Research
Role:	Co-I
ID:	1R01CA237904-01 /FP00005784

Date:	2019 - 2024
Title:	Novel analysis of association between microbiome and treatment infection in AML
Funding Source:	Columbia University
Role:	PD/PI
ID:	FP00005520

Date:	2019 - 2021
Title:	Targeted CD24 reduction promotes progression-free survival in neuroblastoma
Funding Source:	NIH/NCI
Role:	Statistical Analyst
ID:	1R21CA238082-01

Date:	2019 - 2022
Title:	Deciphering the Underlying Biology and Translational Relevance of PD-L2
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP190218

Date:	2019 - 2022
Title:	NK Cell Therapy for Refractory or Relapsed Osteosarcoma
Funding Source:	MDACC
Role:	Collaborator

Date:	2019 - 2023
Title:	OPTIMIST Trial: Optimizing statin intervention for primary prevention of breast cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	FP00005617

Date:	2019 - 2022
Title:	Targeting MELK in triple negative breast cancer metastasis
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP190201

Date:	2019 - 2022
Title:	Patient-derived xenograft derived ex vivo (PDXEx) models as a rapid PDX adaptation to identify metastatic Inflammatory breast cancer (IBC) targeted therapies
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	FP00005703

Date:	2019 - 2020
Title:	Patient-derived xenograft derived ex vivo (PDXEx) models; a rapid PDX adaptation for Inflammatory breast cancer (IBC) targeted drug identification to treat metastatic disease
Funding Source:	Elsa U Pardee Foundation
Role:	Collaborator
ID:	FP00006354

Date:	2019 - 2021
Title:	Lysyl oxidase(LOX): its oncogenic function in triple negative breast cancer and potential target to overcome MEK inhibitor resistance
Funding Source:	Breast Cancer Alliance
Role:	Co-I
ID:	FP00006128

Date:	2018 - 2021
Title:	BC180802: Modulation of PEA15 as a novel therapeutic approach in TNBC
Funding Source:	US Department of Defense
Role:	PD/PI
ID:	FP00005625

Date:	2018 - 2026
Title:	Elucidating Dynamics of Oral Polymicrobial Communities and Designing Synthetic Biofilms to Improve Oral Cancer Outcomes
Funding Source:	NIH/NIDCR
Role:	Co-I
ID:	1R35DE028244-01/FP00004516

Date:	2018 - 2023
Title:	Deciphering the Underlying Biology and Translational Relevance of PD-L2
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1R01CA233653-01 / FP00004761

Date:	2018 - 2023
Title:	Pro-inflammatory Conversion of the PDAC Microenvironment
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA234069-01 / FP00004773

Date:	2018 - 2023
Title:	Pediatric Solid Tumors Comprehensive Data Resource Core
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP180819

Date:	2018 - 2022
Title:	The proteo-genomics of treatment resistance in pediatric cancers: the path to precision therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Biostatistician
ID:	FP00004515

Date:	2018 - 2021
Title:	Pro-Inflammatory Conversion of the PDAC Microenvironment
Funding Source:	Pancreatic Cancer Action Network
Role:	Co-I
ID:	18-65-CURR

Date:	2018 - 2023
Title:	Predisposition to Breast Cancer in Women of African Descent
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA232338-01 / FP00004282

Date:	2018 - 2020
Title:	Effects of Non-conventional pain drugs as single and combination therapy for CIPN
Funding Source:	NIH/NCI
Role:	Statistician
ID:	1R21CA231448-01

Date:	2018 - 2019
Title:	Exercise to decrease the rate of metastasis and improve chemotherapeuticefficacy in Ewing Sarcoma
Funding Source:	Conquer Cancer Foundation
Role:	Collaborator
ID:	FP00003724

Date:	2018 - 2022
Title:	Develop CTC capture technology for both mesenchymal and non-mesenchymal tumors
Funding Source:	NIH/NIBIB
Role:	Co-I
ID:	5R01EB026291-04

Date:	2018 - 2021
Title:	Deciphering the underlying biology and translational relevance of PD-L2
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	FP00005794

Date:	2018 - 2023
Title:	miRNA-140-3p-1 mediated deregulation of cholesterol pathway as a target for prevention of breast cancer
Funding Source:	NIH
Role:	Collaborator
ID:	1R01CA225934-01

Date:	2018 - 2023
Title:	Exploring associations between high-dimensional dynamic microbiome and disease
Funding Source:	NIH
Role:	Co-I
ID:	1R01CA22584-01

Date:	2018 - 2023
Title:	Study of a Novel Deubiquitylase in Medulloblastoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	2 R01 NS079715-05

Date:	2018 - 2022
Title:	Energy balance strategies to increase doxorubicin efficacy and decrease its cardiotoxicity
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	FP00002399

Date:	2018 - 2021
Title:	Microbial and Metabolic influences on UVR-induced Melanoma Driver Mutagenesis
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	FP00002337

Date:	2018 - 2019
Title:	Targeted Inhibition of CD24 Promotes Anti-tumor Effects in Neuroblastoma
Funding Source:	Children's Cancer Research Fund
Role:	Co-I
ID:	FP00004214

Date:	2018 - 2021
Title:	Understanding the Role of Mcl1 in MAPK driven Tumors in TNBC
Funding Source:	American Cancer Society (ACS)
Role:	Co-I
ID:	RSG-17-205-01-TBG

Date:	2017 - 2019
Title:	Development of novel methodology to associate microbiome data with clinical outcomes
Funding Source:	NIH/NCI
Role:	PI
ID:	1R03CA216030-01A1

Date:	2017 - 2019
Title:	Reductive Stress Mediated Chemoresistance: A Novel Therapeutic Target in Acute Myeloblastic Leukemia (AML)
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R21CA218638-01

Date:	2017 - 2020
Title:	Molecular, Immune and Clinical Significance of Obesity in Advanced Melanoma
Funding Source:	Conquer Cancer Foundation
Role:	Co-I
ID:	FP00000184

Date:	2017 - 2022
Title:	Energy Balance to Improve Doxorubicin Response and Decrease Cardiotoxicity
Funding Source:	St. Baldrick's Foundation
Role:	Co-I
ID:	FP0001838

Date:	2017 - 2022
Title:	EWS-FLI-1 and REST regulate tumor vascular Pericytes in Ewing’s Sarcoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA217918-01

Date:	2017 - 2019
Title:	Mutual role of UVR and Skin Microbiome in Generating Melanoma Driver Mutations
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R21E5028410-01

Date:	2017 - 2019
Title:	BC161890: Characterization of a preneoplastic miRNA signature for sporadic TNBC risk across racial populations
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	FP00000674

Date:	2017 - 2019
Title:	(PQ5) Mitochondrial Variability in Melanoma Oncogenesis
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R21CA219564-01

Date:	2017 - 2019
Title:	Preneoplastic MiRNA signature for sporadic TNBC risk across racial populations
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R21CA219219-01

Date:	2017 - 2018
Title:	Reciprocal roles of UVR and Skin Microbiome in the generation of Melanoma Driver Mutations
Funding Source:	Harry J. Lloyd Charitable Trust
Role:	Co-I
ID:	FP00000767

Date:	2017 - 2019
Title:	Role of Skin Microbiome in the generation of Melanoma Driver Mutations
Funding Source:	MELANOMA RSRCH ALLIANCE
Role:	Co-I
ID:	FP00000556

Date:	2017 - 2022
Title:	BET protein antagonist based targeted therapy of Mantle Cell Lymphoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5R01 CA210250-05

Date:	2017 - 2019
Title:	Novel preneoplastic miRNA signature for sporadic TNBC risk across racial populations
Funding Source:	Friends for an Earlier Breast Cancer Test
Role:	Co-I

Date:	2016 - 2019
Title:	Targeting the Glycolysis Pathway to Overcome Resistance to Cancer Immunotherapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Biostatistician
ID:	RP170401

Date:	2016 - 2018
Title:	Unlocking Tumor Immunophenotype in Responders Versus Non-Responders in Metastatic Uveal Melanoma Patients Receiving Immune Checkpoint Blockade
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	5R21CA208609-02

Date:	2016 - 2017
Title:	Melanoma Moon Shot - Prevention Flagship
Funding Source:	The University of Texas MD Anderson Cancer Center Moonshot Program
Role:	Biostatistics Support

Date:	2016 - 2022
Title:	The Role of ENF loss, TLR4 and spinal plasticity in paclitaxel CIPN
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5R01CA200263-05

Date:	2016 - 2019
Title:	Exploiting molecular and metabolic dependencies to optimize personalized therapeutic approaches for melanomas
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP160183

Date:	2015 - 2017
Title:	Method to analyze X-chromosomal genetic data
Funding Source:	NIH/NCI
Role:	PI
ID:	5R03CA192197-02

Date:	2015 - 2018
Title:	A Novel Mitochondrial Inhibitor to Overcome Resistance to MAPLK Inhibition
Funding Source:	Melanoma Research Alliance
Role:	Collaborator
ID:	348483

Date:	2014 - 2019
Title:	The role of the PI3K pathway in immune resistance
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5 R01 CA187076-05

Date:	2013 - 2014
Title:	Molecular Epidemiology of Neuropathic Pain in Head and Neck Cancer
Funding Source:	NIH/NIDCR
Role:	Co-I
ID:	4R01 DE022891-05

Date:	2013 - 2015
Title:	Risk Models for Head and Neck Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	1R03CA165134-01A1

Date:	2011 - 2013
Title:	Risk Modeling Using Mediation Analysis and Bayesian Network Recovery with Application to Smoking Cessation Study
Funding Source:	Duncan Family Institute
Role:	PI
ID:	DFI Mentored Junior Faculty Fellowship

Date:	2010 - 2011
Title:	The Meningioma Consortium: Genome-Wide Association Study
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01 CA151933

Date:	2009 - 2016
Title:	Genome-Wide Association Study of Head and Neck Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5R01 CA131324-05

Selected Publications

Peer-Reviewed Articles

Sheen S, Hasan P, Sun X, Wang J, Tatsui C, Nouri K, Javed S. Retrospective Assessment of Adjacent Fracture Risks in Vertebroplasty, Kyphoplasty, and Bone-Tumor Radiofrequency Ablation. Pain Pract 26(6):e70182, 2026. e-Pub 2026. PMID: 42366910.
Rav E, Sheikh IN, Cha Y, Andersen CR, Baig MU, Harden A, Itzep N, Wang J, Moody K. Topical Amitriptyline, Ketamine, and Lidocaine Cream for Neuropathic Pain Control in Pediatric Oncology Patients. J Pain Symptom Manage, 2026. e-Pub 2026. PMID: 42362167.
Wang J, Ning J, Shaitelman SF, Lin HY, Bedrosian I, Shen Y. Radiation Therapy De-escalation in Breast Cancer Patients With Pathologic Complete Response: An Integrated Analysis Using Real-World and Simulated Data. Int J Radiat Oncol Biol Phys, 2026. e-Pub 2026. PMID: 42173325.
Gowda K, Gupta M, Aguilar A, Cruz C, Warner A, Rodriguez ER, Ahmed S, Cuglievan B, Milam J, Freyer DR, Miller KA, Aune G, Eshelman-Kent D, Albritton K, Koutroumpakis E, Roth ME, Wang J, Hildebrandt MAT. Survival After Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma. Eur J Haematol, 2026. e-Pub 2026. PMID: 42134679.
Kao G, Javed S, De Asis O, Wang J, Sun X. Bridging the Gap: Engagement with Behavioral Health for Pain Management Among Oncology Patients. J Pain Symptom Manage, 2026. e-Pub 2026. PMID: 42105883.
Brown A, Nwankwo A, Ege E, Wang J, Sun X, Karri J, Dougherty PM, Abdi S, Huh B, Souza RS, Javed S. Risk Factors of Chemotherapy-Induced Painful Peripheral Neuropathy: A Retrospective Study from A Single Cancer Center. Pain Physician 29(3):269-279, 2026. e-Pub 2026. PMID: 42263313.
Offer K, Reif M, Andersen C, Wang J, Gordon N, Moody K. MISTOSUS: a phase II trial of Viscum album extract adjuvant therapy for relapsed resectable osteosarcoma. Future Oncol 22(8):901-909, 2026. e-Pub 2026. PMID: 41789811.
Zhang S, Jin Y, Jia Z, Xia X, Li Y, Wang Q, Wang J, Wang J, Chandra J, Friedman GK, Li S. Fgl2-knockout tumor cells serve as a vaccine inducing long-duration brain-resident memory T cells that reject subsequent intracranial tumor cell challenges. Cancer Lett 640:218215, 2026. e-Pub 2026. PMID: 41380903.
Fiskus W, Mill CP, Piel J, Collins M, Hentemann M, Cuglievan B, Birdwell CE, Das K, Davis JA, Hou H, Jain A, Malovannaya A, Flores LB, Kadia TM, Daver N, Sasaki K, Takahashi K, Hammond D, Wang J, Loghavi S, Su X, DiNardo CD, Delwel R, Bhalla KN. Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML. Hemasphere 10(1):e70289, 2026. e-Pub 2026. PMID: 41551728.
Ganji-Angirekula S, Segada N, Hasan P, Grace PM, Wang J, Sun X, Javed S. Prevalence of PD-1 Inhibitor-Associated Peripheral Neuropathy: A Retrospective Cohort Study. Life 16(1):31, 2025. e-Pub 2025.
Jaffery R, Zhao Y, Ahmed S, Schumacher JG, Ahn J, Shi L, Wang Y, Tan Y, Zhang J, Chen K, Tawbi H, Wang J, Schwarzschild MA, Peng W, Chen X. Soluble immune factor profiles in blood and CSF associated with LRRK2 mutations and Parkinson's disease. NPJ Parkinsons Dis 11(1):365, 2025. e-Pub 2025. PMID: 41309625.
Mireles J, Huh A, Wang J, Sun X, Nalli S, Javed S, Huh BK. Impact of Glycemic Control on Surgical Site Infections in Neuromodulation Pain Procedures: A Retrospective Analysis. Pain Physician 28(6):539-544, 2025. e-Pub 2025. PMID: 41337766.
Hu J, Singh H, Jin Y, Zhang W, Wang J, Xia X, Somaiah N, Gorlick R, Li S. Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas. Proc Natl Acad Sci U S A 122(41):e2507542122, 2025. e-Pub 2025. PMID: 41052334.
Moody K, Stein J, Levine D, Madni A, Andersen CA, Heaton A, Rajan AP, Petropoulos D, Wang J, Kramer D. The use of Firgun to improve burnout and workplace civility in a Pediatric Cancer Center. Advances in Cancer Education and Quality Improvement 1(2):2, 2025. e-Pub 2025.
Schumacher JG, Zhang X, Macklin EA, Wang J, Bayati A, Dijkstra JM, Watanabe H, Schwarzschild MA, Cortese M, Zhang X, Chen X. Baseline alpha-synuclein seeding activity and disease progression in sporadic and genetic Parkinson's disease in the PPMI cohort. EBioMedicine 119:105866, 2025. e-Pub 2025. PMID: 40773926.
Mughees M, Tacam MJ, Tan AW, Pitner MK, Iles LR, Hu X, S Villodre E, Debeb BG, Kogawa T, Lim B, Layman RM, Woodward WA, Ueno NT, Tripathy D, Krishnamurthy S, Qi Y, Pusztai L, Wang J, Gandhi V, Bartholomeusz G, Bartholomeusz C. Inhibition of MCL-1 and MEK overcomes MEK inhibitor resistance in triple-negative and inflammatory breast cancers. Mol Cancer Ther, 2025. e-Pub 2025. PMID: 40358476.
Sheen S, Hasan P, Sun X, Wang J, Tatsui C, Nouri L, Javed S. Retrospective analysis of cement extravasation rates in vertebroplasty, kyphoplasty, and bone tumor radiofrequency ablation. Journal of Clinical Medicine, 2025. e-Pub 2025.
Farias RM, Jiang Y, Levy EJ, Huang C, Wang J, Burton EM, Cohen L, Ajami N, Wargo JA, Daniel CR, McQuade JL. Diet and Immune Effects Trial (DIET)- A randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy. BMC Cancer 24(1):1493, 2024. e-Pub 2024. PMID: 39633321.
Huang X, Wang J, Ning J. The win ratio approach in Bayesian monitoring for two-arm phase II clinical trial designs with multiple time-to-event endpoints. Statistics in Medicine 43(30):5922-5934, 2024. e-Pub 2024. PMID: 39582325.
Wang J, Jiang X, Ning J. Evaluating dynamic and predictive discrimination for recurrent event models: use of a time-dependent C-index. Biostatistics 25(4):1140-1155, 2024. e-Pub 2024. PMID: 37952117.
Yang Y, Zhou Y, Wang J, Zhou Y, Watowich S, Kleinerman E. CD103+ cDC1 dendritic cell vaccine therapy for osteosarcoma lung metastases. Cancers (Basel) 16(19), 2024. e-Pub 2024. PMID: 39409873.
Ragoonanan D, Abdel-Azim H, Sharma A, Bhar S, McArthur J, Madden R, Rahrig A, Bajwa R, Wang J, Sun V, Wright M, Lassiter R, Shoberu B, Kawedia J, Khazal SJ, Mahadeo KM. Retrospective analysis of veno-occlusive disease/sinusoidal obstruction syndrome in paediatric patients undergoing hematopoietic cell transplantation -a multicentre study. Lancet Reg Health Am 33:100728, 2024. e-Pub 2024. PMID: 38616918.
Fiskus W, Piel J, Collins M, Hentemann M, Cuglievan B, Mill C, Birdwell C, Das K, Davis J, Hou H, Jain A, Malovannaya A, Kadia T, Daver N, Sasaki K, Takahashi K, Hammond D, Reville P, Wang J, Loghavi S, Sen R, Ruan X, Su X, Flores L, DiNardo C, Bhalla K. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor. Blood 143(20):2059-2072, 2024. e-Pub 2024. PMID: 38437498.
Cinciripini PM, Wetter DW, Wang J, Yu R, Kypriotakis G, Kumar T, Robinson JD, Cui Y, Green CE, Bergen AW, Kosten TR, Scherer SE, Shete S. Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample. Sci Rep 14(1):6385, 2024. e-Pub 2024. PMID: 38493193.
Wooten SV, Amini B, Roth M, Leung CH, Wang J, Hildebrandt MAT, Kleinerman E. Adolescent and Young Adult Hodgkin Lymphoma Patients at Risk for Subcutaneous Fat Gain During Early Cancer Treatment: A Brief Report. Leuk Lymphoma 65:62-68, 2024. e-Pub 2024. PMID: 37878765.
Hu J, Lazar AJ, Ingram D, Wang WL, Zhang W, Jia Z, Ragoonanan D, Wang J, Xia X, Mahadeo K, Gorlick R, Li S. Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models. J Immunother Cancer 12(1), 2024. e-Pub 2024. PMID: 38199607.
Jeyabal P, Bhagat A, Wang F, Roth M, Livingston JA, Gilchrist SC, Banchs J, Hildebrandt MAT, Chandra J, Deswal A, Koutroumpakis E, Wang J, Daw NC, Honey TA, Kleinerman ES. Circulating microRNAs and cytokines as prognostic biomarkers for doxorubicin-induced cardiac injury and for evaluating the effectiveness of an exercise intervention. Clin Cancer Res 29(21):4430-4440, 2023. e-Pub 2023. PMID: 37651264.
Zaky W, Ragoonanan D, Batth I, Dao L, Wang J, Xia X, Daw NC, Gill JB, Khatua S, Li S. Automated Capture and Analysis of Circulating Tumor Cells in Pediatric, Adolescent and Young Adult Patients with Central Nervous System Tumors. Cancers (Basel) 15(15), 2023. e-Pub 2023. PMID: 37568669.
Xie X, Chauhan GB, Edupuganti R, Kogawa T, Park J, Tacam M, Tan AW, Mughees M, Vidhu F, Liu DD, Taliaferro JM, Pitner MK, Browning LS, Lee JH, Shen Y, Wang J, Ueno NT, Krishnamurthy S, Hortobagyi GN, Tripathy D, Van Laere SJ, Bartholomeusz G, Dalby KN, Bartholomeusz C. Maternal embryonic leucine zipper kinase is associated with metastasis in triple-negative breast cancer. Cancer Res Commun 3(6):1078-1092, 2023. e-Pub 2023. PMID: 37377604.
Hahn AW, Menk AV, Rivadeneira DB, Augustin RC, Xu M, Li J, Wu X, Mishra AK, Gide TN, Quek C, Zang Y, Spencer CN, Menzies AM, Daniel CR, Hudgens CW, Nowicki T, Haydu LE, Khan MAW, Gopalakrishnan V, Burton EM, Malke J, Simon JM, Bernatchez C, Putluri N, Woodman SE, Gopal Y N V, Guerrieri R, Fischer GM, Wang J, Wani KM, Thompson JF, Lee JE, Hwu P, Ajami N, Gershenwald JE, Long GV, Scolyer RA, Tetzlaff MT, Lazar AJ, Schadendorf D, Wargo JA, Kirkwood JM, DeBerardinis RJ, Liang H, Futreal A, Zhang J, Wilmott JS, Peng W, Davies MA, Delgoffe GM, Najjar YG, McQuade JL. Obesity is associated with altered tumor metabolism in metastatic melanoma. Clin Cancer Res 29(1):154-164, 2023. e-Pub 2022. PMID: 36166093.
Aggarwal P, Hutcheson KA, Yu R, Wang J, Fuller CD, Garden AS, Goepfert RP, Rigert J, Mott FE, Lu C, Lai SY, Gunn GB, Chambers MS, Li G, Wu CC, Hanna EY, Sturgis EM, Shete S. Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors. Sci Rep 12(1):6662, 2022. e-Pub 2022. PMID: 35459784.
Sheikh IN, Miller J, Shoberu B, Andersen CR, Wang J, Williams LA, Mahadeo KM, Robert R. Using the MDASI-Adolescent for early symptom identification and mitigation of symptom impact on daily living in adolescent and young adult stem cell transplant patients. Children (Basel) 9(1):19, 2021. e-Pub 2021. PMID: 35053644.
Dong J, White S, Nielsen K, Banchs J, Wang J, Botz GH, Nates JL. Tricuspid Annular Plane Systolic Excursion is a Predictor of Mortality for Septic Shock. Intern Med J 51(11):1854-1861, 2021. e-Pub 2020. PMID: 32618101.
John JC, Wang J, McNeill LHM, Basen-Engquist K, Hoover DS, Daniel CR, Strong LL. A mixed methods study on engagement and satisfaction with a digitally-enhanced pilot intervention among African American and Hispanic women. J Immigr Minor Health 23(5):1011-1020, 2021. e-Pub 2021. PMID: 33043411.
Wang J, Ma J, Cai C, Daver N, Ning J. A Bayesian hierarchical monitoring design for phase II cancer clinical trials: incorporating information on response duration into monitoring rules. Stat Med 40(21):4629-4639, 2021. e-Pub 2021. PMID: 34101217.
Wang J, Reyes-Gibby CC, Shete S. An approach to analyze longitudinal zero-inflated microbiome count data using two-stage mixed effects models. Statistics in Biosciences 13(2):267-290, 2021. e-Pub 2021.
Chung M, Benkli B, Roldan C, Qing Y, Wang J, Huh B. Subanesthetic ketamine in the ambulatory setting for refractory cancer pain: a 6-year retrospective at a cancer center. Pain Manag 11(3):267-276, 2021. e-Pub 2021. PMID: 33533283.
Yan J, Zhao Q, Wang J, Tian X, Wang J, Xia X, Ott M, Rao G, Heimberger AB, Li S. FGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells. Cancer Lett 506:83-94, 2021. e-Pub 2021. PMID: 33676940.
Cuglievan B, Berkman A, Dibaj S, Wang J, Andersen CR, Livingston JA, Gill J, Bleyer A, Roth M. Impact of lagtime, health insurance type and income status at diagnosis on the long-term survival of adolescent and young adult cancer patients. J Adolesc Young Adult Oncol 10(2):164-174, 2021. e-Pub 2021. PMID: 32678703.
Ragoonanan D, Khazal SJ, Wang J, Payne A, Kohorst M, Harden A, Tewari P, Petropoulos D, Shoberu B, Kebriaei P, Mahadeo KM, Tambaro FP. Improved detection of sinusoidal obstructive syndrome using pediatric-AYA diagnostic criteria and severity grading. Bone Marrow Transplant 56(1):175-184, 2021. e-Pub 2021. PMID: 32665674.
Hu J, Zhao Q, Kong LY, Wang J, Yan J, Xia X, Jia Z, Heimberger AB, Li S. Regulation of tumor immune suppression and cancer-cell survival by CXCL1/2 elevation in glioblastoma multiforme. Sci Adv 7(5), 2021. e-Pub 2021. PMID: 33571109.
Dao L, Ragoonanan D, Batth I, Satelli A, Foglesong J, Wang J, Zaky W, Gill JB, Liu D, Albert A, Gordon N, Huh W, Harrison D, Herzog C, Kleinerman E, Gorlick R, Daw N, Li S. Prognostic Value of Cell-Surface Vimentin-Positive CTCs in Pediatric Sarcomas. Front Oncol 11:760267, 2021. e-Pub 2021. PMID: 34956881.
Wang J, Ning J, Shete S. Mediation model with a categorical exposure and a censored mediator with application to a genetic study. PLoS One 16(10):e0257628, 2021. e-Pub 2021. PMID: 34637449.
Batth IS, Dao L, Satelli A, Mitra A, Yi S, Noh H, Li H, Brownlee Z, Zhou S, Bond J, Wang J, Wang J, Gill J, Sholler GS, Li S. Cell Surface Vimentin Positive Circulating tumor cell-based relapse prediction in a long-term longitudinal study of post-remission neuroblastoma patients. Int J Cancer 147(12):3550-3559, 2020. e-Pub 2020. PMID: 32506485.
Reyes-Gibby CC, Wang J, Zhang L, Peterson CB, Do KA, Jenq RR, Shelburne S, Shah DP, Chambers MS, Hanna EY, Yeung SJ, Shete S. Oral microbiome and onset of oral mucositis in patients with squamous cell carcinoma of the head and neck. Cancer 126(23):5124-5136, 2020. e-Pub 2020. PMID: 32888342.
Kohorst MA, Khazal SJ, Tewari P, Petropoulos D, Mescher B, Wang J, Mahadeo KM, Kelley JM. Transfusion reactions in pediatric and adolescent young adult haematology oncology and immune effector cell patients. EClinicalMedicine 26:100514, 2020. e-Pub 2020. PMID: 32964199.
Berkman AM, Livingston JA, Merriman K, Hildebrandt M, Wang J, Dibaj S, McQuade J, You N, Ying A, Barcenas C, Bodurka D, DePombo A, Lee HJ, de Groot J, Roth M. Long-term survival among 5-year survivors of adolescent and young adult cancer. Cancer 126(16):3708-3718, 2020. e-Pub 2020. PMID: 32484922.
Shete S, Liu H, Wang J, Yu R, Sturgis EM, Li G, Dahlstrom KR, Liu Z, Amos CI, Wei Q. A Genome-Wide Association Study Identifies Two Novel Susceptible Regions for Squamous Cell Carcinoma of the Head and Neck. Cancer Res 80(12):2451-2460, 2020. e-Pub 2020. PMID: 32276964.
Peng W, Williams LJ, Xu C, Melendez B, McKenzie JA, Chen Y, Jackson HL, Voo KS, Mbofung RM, Leahey SE, Wang J, Lizee G, Tawbi HA, Davies MA, Hoos A, Smothers J, Srinivasan R, Paul EM, Yanamandra N, Hwu P. Anti-OX40 antibody directly enhances the function of tumor-reactive CD8+ T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma. Clin Cancer Res 25(21):6406-6416, 2019. e-Pub 2019. PMID: 31371342.
Yennu-Nanda VP, Gammon S, Prasad R, Knighton B, Pisaneschi F, Roszik J, Feng N, Johnson S, Pramanik S, Sudderth J, Sui D, Hudgens C, Fischer GM, Deng W, Reuben A, Peng W, Wang J, McQuade JL, Tetzlaff MT, Di Francesco ME, Marszalek J, Piwnica-Worms D, DeBerardinis RJ, Davies MA. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. Clin Cancer Res 25(21):6429-6442, 2019. e-Pub 2019. PMID: 31439581.
Wang J, Ning J, Shete S. Mediation analysis in a case-control study when the mediator is a censored variable. Stat Med 38(7):1213-1229, 2019. e-Pub 2019. PMID: 30421436.
Yan J, Zhao Q, Gabrusiewicz K, Kong LY, Xia X, Wang J, Ott M, Xu J, Davis RE, Huo L, Rao G, Sun SC, Watowich SS, Heimberger AB, Li S. FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nat Commun 10(1):448, 2019. e-Pub 2019. PMID: 30683885.
Heredia NI, Wilkinson AV, Forman MR, Christie IC, Wang J, Daniel CR, Zhao H, Bondy ML, Strong LL. Longitudinal associations of family functioning with body mass index in Mexican-origin adolescents living in the U.S. Prev Med 118:309-316, 2019. e-Pub 2019. PMID: 30419254.
Wang J, Shete S. Estimation of indirect effect when the mediator is a censored variable. Stat Methods Med Res 27(10):962280217690414, 2018. e-Pub 2018. PMID: 28132585.
Reyes-Gibby CC, Wang J, Yeung SJ, Chaftari P, Yu RK, Hanna EY, Shete S. Genome-wide association study identifies genes associated with neuropathy in patients with head and neck cancer. Sci Rep 8(1):8789, 2018. e-Pub 2018. PMID: 29884837.
Mechanic LE, Lindström S, Daily KM, Sieberts SF, Amos CI, Chen HS, Cox NJ, Dathe M, Feuer EJ, Guertin MJ, Hoffman J, Liu Y, Moore JH, Myers CL, Ritchie MD, Schildkraut J, Schumacher F, Witte JS, Wang W, Williams SM, Participants UC, Contributors UC, Gillanders DM. Up For A Challenge (U4C) - Stimulating Innovation in Breast Cancer Genetic Epidemiology. PLOS Genetics 13(9):e1006945, 2017. e-Pub 2017.
Wang J, Talluri R, Shete S. Selection of X-chromosome inactivation model. Cancer Inform 16:1176935117747272, 2017. e-Pub 2017. PMID: 29308008.
Reyes-Gibby CC, Melkonian SC, Wang J, Yu RK, Shelburne SA, Lu C, Gunn GB, Chambers MS, Hanna EY, Yeung SJ, Shete S. Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: an informative gene network analysis. PLoS One 12(7):e0180396, 2017. e-Pub 2017. PMID: 28678827.
Reyes-Gibby CC, Wang J, Silvas MR, Yu RK, Hanna EY, Shete S. Genome-wide association study suggests common variants within RP11-634B7.4 gene influencing severe pre-treatment pain in head and neck cancer patients. Scientific Reports 6:34206, 2016. e-Pub 2016. PMID: 27670397.
Zhu X, Wang J, Peng B, Shete S. Empirical estimation of sequencing error rates using smoothing splines. BMC Bioinformatics 17:177, 2016. e-Pub 2016. PMID: 27102907.
Reyes-Gibby CC, Wang J, Silvas M, Yu R, Yeung SC, Shete S. MAPK1/ERK2 as novel target genes for pain in head and neck cancer patients. BMC Genet 17(1):40, 2016. e-Pub 2016. PMID: 26872611.
Reyes-Gibby CC, Wang J, Yeung SC, Shete S. Informative gene network for chemotherapy-induced peripheral neuropathy. BioData Min 8:24, 2015. e-Pub 2015. PMID: 26269716.
Reyes-Gibby CC, Yuan C, Wang J, Yeung SC, Shete S. Gene network analysis shows immune-signaling and ERK1/2 as novel genetic markers for multiple addiction phenotypes: alcohol, smoking and opioid addiction. BMC Syst Biol 9:25, 2015. e-Pub 2015. PMID: 26044620.
Wang J, Yu R, Shete S. X-chromosome genetic association test accounting for X-inactivation, skewed X-inactivation, and escape from X-inactivation. Genet Epidemiol 38(6):483-93, 2014. e-Pub 2014. PMID: 25043884.
Archer NP, Wilkinson AV, Ranjit N, Wang J, Zhao H, Swann AC, Shete S. Genetic, psychosocial, and demographic factors associated with social disinhibition in Mexican-origin youth. Brain Behav 4(4):521-30, 2014. e-Pub 2014. PMID: 25161819.
Talluri R, Wang J, Shete S. Calculation of exact p-values when SNPs are tested using multiple genetic models. BMC Genet 15(1):75, 2014. e-Pub 2014.
Wang J, Yu R, Shete S. Comparison of multilevel model and the family-based association test (FBAT) for identifying SNPs associated with systolic and diastolic blood pressure using GAW18 simulated data. BMC Proceedings 8(Suppl):S30, 2014. e-Pub 2014.
Reyes-Gibby CC, Wang J, Spitz M, Wu X, Yennurajalingam S, Shete S. Genetic variations in Interleukin-8 and Interleukin-10 are associated with pain, depressed mood, and fatigue in lung cancer patients. J Pain Symptom Manage 46(2):161-172, 2013. e-Pub 2013. PMID: 23149083.
Wilkinson AV, Gabriel KP, Wang J, Bondy ML, Dong Q, Wu X, Shete S, Spitz MR. Sensation seeking genes and physical activity in youth. Genes Brain Behav 12(2):181-8, 2013. e-Pub 2013. PMID: 23190435.
Wang J, Shete S. Analysis of secondary phenotype involving the interactive effect of the secondary phenotype and genetic variants on the primary disease. Ann Hum Genet 76(6):484-99, 2012. e-Pub 2012. PMID: 22881407.
Wilkinson AV, Bondy ML, Wu X, Wang J, Dong Q, D'Amelio AM, Prokhorov AV, Pu X, Yu RK, Etzel CJ, Shete S, Spitz MR. Cigarette experimentation in Mexican origin youth: psychosocial and genetic determinants. Cancer Epidemiol Biomarkers Prev 21(1):228-38, 2012. e-Pub 2012. PMID: 22028400.
Wang J, Spitz MR, Amos CI, Wu X, Wetter DW, Cinciripini PM, Shete S. Method for evaluating multiple mediators: mediating effects of smoking and COPD on the association between the CHRNA5-A3 variant and lung cancer risk. PLoS One 7(10):e47705, 2012. e-Pub 2012. PMID: 23077662.
Wang J, Shete S. Power and type I error results for a bias-correction approach recently shown to provide accurate odds ratios of genetic variants for the secondary phenotypes associated with primary diseases. Genet Epidemiol 35(7):739-43, 2011. e-Pub 2011. PMID: 21769937.
Wang J, Shete S. Estimation of odds ratios of genetic variants for the secondary phenotypes associated with primary diseases. Genet Epidemiol 35(3):190-200, 2011. e-Pub 2011. PMID: 21308766.
Wang J, Shete S. Testing Hardy-Weinberg proportions in a frequency-matched case-control genetic association study. PLoS One 6(11):e27642, 2011. e-Pub 2011. PMID: 22110703.
Huang Z, Wang J, Wu CC, Houlston RS, Bondy ML, Shete S. False-Negative-Rate based approach for selecting top single-nucleotide polymorphisms in the first stage of a two-stage genome-wide association study. Stat Interface 4(3):359-371, 2011. e-Pub 2011. PMID: 23060946.
Wang J, Shete S. A powerful hybrid approach to select top SNPs for genome-wide association study. BMC Genet 12(1):3, 2011. e-Pub 2011. PMID: 21211033.
Wang J, Spitz MR, Amos CI, Wilkinson AV, Wu X, Shete S. Mediating effects of smoking and chronic obstructive pulmonary disease on the relation between the CHRNA5-A3 genetic locus and lung cancer risk. Cancer 116(14):3458-3462, 2010. e-Pub 2010. PMID: 20564069.
Wang J, Shete S. Using both cases and controls for testing hardy-weinberg proportions in a genetic association study. Hum Hered 69(3):212-218, 2010. e-Pub 2010. PMID: 20203526.
Wang J, Shete S. Is the tail strength measure more powerful for genetic association test? And tail strength to combine two p-values: their correlation cannot be ignored: Authors reply. Am J Hum Genet 84(2):298-300, 2009. e-Pub 2009.
Wang J, Shete S. A test for genetic association that incorporates information about deviation from Hardy-Weinberg proportions in cases. Am J Hum Genet 83(1):53-63, 2008. e-Pub 2008. PMID: 18589394.
Wang J, Liu E, Luo G. Analysis of time-cost-quality tradeoff optimization in project management. Journal of System Engineering 19:148-154, 2004. e-Pub 2004.
Luo G, Liu E, Wang J. Resource planning optimization in network schedule using genetic algorithms. Journal of Tianjin University 37:179-183, 2004. e-Pub 2004.
Gupta M, Brandt A, Clay-Gilmour A, Xiao Q, Wang J, Montealegre JR, Balachandran DD, Stavinoha P, Choi E, Livingston J, Milam J, Freyer D, Miller KA, Merriman K, Peterson SK, Roth ME, Hildebrandt MAT. Impact of Sleep Behavior and Chronotype Polygenic Risk Scores on Health Outcomes in Survivors of AYA Cancer: the MD Anderson AYA Cancer Survivorship Study (AYACSS).
Wang J, Huang X, Wang Y, Ning J. Bayesian Response-Adaptive Phase II Trial Designs Using the Win Ratio for Multiple Time-to-Event Outcomes. Statistics in Medicine.
Peng W, Zheng N, Liang X, Chen Y, Chen S, Creasy C, Bernatchez C, Tetzlaff M, Wang Y, Menon P, Dai Y, Hinchcliff E, Wang J, Wang L, Jazaeri A, Hwu P, Varadarajan N, Davies M, Hou J. AXL Deficiency in Melanoma Promotes Resistance to Adoptive T Cell Therapy. Cancer Research.
Nadim A, Wang J, Daniel-MacDougall C. Randomized dietary fiber intervention in melanoma patients on immunotherapy: the DIET trial. Nature Medicine.
Choi E, Wang J, Roth ME. Sleep Disturbance in Survivors of Adolescent and Young Adult Cancer: A Nationally Representative, Matched Case-Control Study. Cancer.
Enaohwo ON, Wang J, Sun X, Saved J. Impact of Tunneling on Lead Migration in Peripheral Nerve Stimulation: A Retrospective Cohort Study. Neuromodulation: Technology at the Neural Interface.
Schumacher JG, Zhang X, Wang J, Dijkstra JM, Watanabe H, Gao X, Cortese M, Macklin EA, Schwarzschild MA, Chen X. Prevalent MC1R variants predict accelerated motor decline in Parkinson's disease. JAMA Neurology.
Sheen S, Hasan P, Sun X, Wang J, Chung M, Javed S. Comparative Safety of Radiofrequency Ablation with Vertebral Augmentation Versus Kyphoplasty and Vertebroplasty in Pathologic Vertebral Compression Fractures: A Retrospective Cohort Study. Journal of Medical Imaging and Radiation Oncology.
LaVoy EC, Roth M, Weather S, Wang J, Andersen C, Amsbaugh M, Kasembeli MM, Whisenant M, Kelly D, Escalante C, Pan E, Parker N, Vargo A, Blevins J, Damron E, Gibson J, LaCourt T, Swartz MC. Cancer-related fatigue and its biological contributors in young adult brain tumor survivors: effects of a tele-exercise intervention (RISE-YA) – study protocol for a randomized controlled trial. BMJ Open.
Sheen S, Bansal V, Wang J, Sun X, Javed S. Periprocedural Wound Complication Risks in Cancer Pain Patients Following Targeted Cancer Therapy: A Retrospective Analysis. Cancer Reports.
Bansal V, Mach S, Wang J, Sun X, Javed S. Spinal Cord or Dorsal-Root Ganglion Stimulator Explant Rate Among Cancer Patients with Cancer-Pain: Retrospective Study. Pain Practice.
Warner AN, Brandt A, Wang J, Albritton K, Eshelman-Kent D, Aune G, Ahmed S, Xiao Q, Roth ME, Banchs J, Koutroumpakis E, Hildebrandt MAT. Investigation of a polygenic risk score for ejection fraction and cardiac function among survivors of adolescent and young adult cancer. PLoS One.
Zhang Y, Wang J, Shen J, Galloway-Pena J, Shelburne S, Wang L, Hu J. Inverse probability weighting-based mediation analysis for microbiome data. Bioinformatics.
Michel E, Kao G, Wang J, Sun X, Javed S. Opioids, Options and Openness: Chronic Pain Patients’ Beliefs and Understanding of Treatment Alternatives. Pain Medicine.

Professional Educational Materials

Wang J. Tree-based Methods. GSBS Modern Nonparametrics Course, 2019.
Shaw J, Csibrik K, Wang J, Tang Y, Ramos E. Impacts of Slow the Flow Colorado on outdoor water use. Center for ReSource Conservation, 2007.
Wang J. Recovering Bayesian networks with applications to gene regulatory networks. University of Colorado at Boulder, 2007.
Baker A, Jung M, Lee C, Maslova I, Morton M, Wang J. Analysis of biological interaction networks for drug discovery. Proceedings of 12th Industrial Mathematical & Statistical Modeling Workshop, 2006.
Wang J. Analysis of time-cost-quality tradeoff optimization in project management. Tianjin University, 2002.
Liu EL, Lu LN, Luo G, Wang J. The application of decision-making to bid under risks. International Conference on Modern Industrial Engineering and Engineering Management in New Century, 2001.
Liu EL, Wang J, Luo G. Project bidding decision based on fuzzy logic. International Conference on Modern Industrial Engineering and Engineering Management in New Century, 2001.
Wang J. Analysis of time-cost optimization in project management. Tianjin University, 1999.

Abstracts

Wang J, Huang X, Ning J. The Bayesian Monitoring Using the Win Ratio for Phase II Trials with Multiple Time-to-Event Endpoints. 2026 Joint Statistical Meetings, 2026. e-Pub 2026.
Wang J, Huang X, Ning J. A Bayesian Monitoring Approach Based on the Win Ratio for Randomized Phase II Trials with Multiple Time-to-Event Outcomes. IMS Annual Meeting 2026, 2026. e-Pub 2026.
LaVoy EC, Roth ME, Weather S, Wang J, Andersen C, Amsbaugh M, Kasembeli MM, Whisenant M, Kelly D, Escalante C, Pan E, Parker N, Vargo A, Blevins J, Damron E, Gibson J, LaCourt T, Swartz MC. RISE-YA: a novel intervention for young adult brain tumor survivors with cancer related fatigue-Study Protocol for a randomized controlled trial. International Society of Exercise Oncology Conference 2026, 2026. e-Pub 2026.
Li S, Hu J, Singh H, Jin Y, Zhang W, Wang J, Xia X, Somaiah N, Gorlick R. Collagen-disrupting TIL-cell therapy for sarcoma. 2026 ASPHO Conference, 2026. e-Pub 2026.
Qiu Y, Dizman N, Jiang Y, Farias RM, Holly AE, Levy EJ, Hwang CH, Klein L, Rains JK, Sule AA, Sirmans E, Burton EM, Wang J, Wang MKK, Ikeguchi A, Oliva I, Patel S, Diab A, Tawbi HA, Amaria RN, Davies MA, Wargo JA, Daniel-MacDougall C, McQuade JL. A randomized controlled trial of a high fiber diet intervention (HFDI) in patients with melanoma receiving immune checkpoint blockade (ICB). SITC 39th Annual Meeting & Pre-Conference Programs, 2024. e-Pub 2024.
Wang J, Jiang X, Ning J. Assessing dynamic and predictive discrimination in recurrent event models using a time-dependent C-Index, 2024. e-Pub 2024.
Wang J, Jiang X, Ning J. A time-dependent C-index to evaluate dynamic and predictive discrimination for recurrent event models, 2024. e-Pub 2024.
Villarreal EG, LaVoy E, Lacourt TE, Waterman G, Pan E, Roth M, Weathers SP, Bai J, King T, Wang J, Swartz MC. Developing a physical activity intervention for adolescent and young adult central nervous system tumor survivors. American College of Sports Medicine 71st Annual Meeting, 2024. e-Pub 2024.
Mughees M, Tan A, Iles L, White M, Tripathy D, Krishnamurthy S, Wang J, Woodward WA, Bartholomeusz G, Bartholomeusz C. Combined inhibition of MCL-1 and MEK reduces tumor growth in a triple-negative/inflammatory breast cancer, MEK-resistant xenograft mouse model. AACR Annual Meeting 2024, 2024. e-Pub 2024.
Wang J, Ma J, Cai C, Daver N, Ning J. A Bayesian Hierarchical Monitoring Design for Single-Arm Phase II Cancer Clinical Trials, 2024. e-Pub 2024.
Wang J, Ning J, Shete S. Mediation analysis with a categorical exposure and a censored mediator in genetic studies, 2023. e-Pub 2023.
Farias RM, Jiang Y, Jenkins CA, Kus TM, Levy E, Montalvo M, Rains J, Wang J, Duncan S, Burton EW, Ajami E, Wargo JA, Daniel-MacDougall C, McQuade JL. The DIET study: A randomized controlled trial of a high fiber diet in cancer patients (pts) receiving immune checkpoint blockade (ICB), 2023. e-Pub 2023.
Rav E, Sarkar S, Idemmili R, Kramer D, Stein J, Levine D, Madni A, Andersen C, Wang J, Rajan A, Heaton A, Moody K. Firgun: The Art of Using Meaningful Recognition to Improve the Work Environment Among A Pediatric Oncology Team, 2023. e-Pub 2023.
Zhang Y, Wang J, Shen J, Galloway-Pena J, Shelburne S, Wang L, Hu J. Inverse Probability Weighting-based Mediation Analysis for Microbiome Data, 2022. e-Pub 2022.
Wang J, Reyes-Gibby C, Shete S. A two-stage mixed effects model to analyze longitudinal zero-inflated microbiome count data, 2022. e-Pub 2022.
Wang J, Ma J, Cai C, Daver N, Ning J. A Bayesian Hierarchical Monitoring Design for Phase II Clinical Trials: Incorporating Information on Response Duration, 2022. e-Pub 2022.
Zhang Y, Wang J, Shen J, Galloway-Pena J, Shelburne S, Wang L, Hu J. Inverse Probability Weighting-based Mediation Analysis for Microbiome Data, 2022. e-Pub 2022.
Jiang Y, Mousavi DC, Kus TM, Levy E, Montalvo M, Wang J, Ajami N, Wargo JA, Daniel-MacDougall C, McQuade JL. Impact of a whole foods based high fiber diet on gut microbiome in melanoma survivors, 2021. e-Pub 2021.
Wang J, Reyes-Gibby C, Shete S. Analyzing Longitudinal Zero-inflated Oral Microbiome Count Data using Two-stage Mixed Effects Models, 2021. e-Pub 2021.
Swartz MC, Roth M, George GC, Livingston JA, Wells SJ, Andersen C, Wang J, Peterson SK. Satisfaction with and recommendations to improve telehealth visits among adolescents and young adults with cancer during the COVID-19 pandemic, 2021. e-Pub 2021.
Wang J, Ning J, Shete S. Mediation analysis with a censored mediator with application to a candidate gene case-control study, 2020. e-Pub 2020.
Wang J, Ning J, Shete S. Mediation analysis in a case-control study when the mediator is a censored variable, 2019. e-Pub 2019.
Wang J, Ning J, Shete S. Estimation of mediating effect in a mediation model with a censored mediator in a case-control study, 2019. e-Pub 2019.
Wang J, Ning J, Shete S. Mediation analysis with a censored mediator in a case–control study, 2019. e-Pub 2019.
Yan J, Zhao Q, Gabrusiewicz K, Kong LY, Xia X, Wang J, Ott M, Xu J, Davis RE, Huo L, Rao G, Sun SC, Watowich SS, Heimberger AB, Li S. Knockout immune regulator FGL2 in tumor cells impairs tumor progression in the CNS by facilitating CD103+ dendritic cell differentiation, 2019. e-Pub 2019.
John JC, Wang, J, McNeill LM, Basen-Engquist K, Hoover DS, Daniel-MacDougall CR, Strong LL. A Process Evaluation of Satisfaction and Engagement Measures from Project FITT: A Mixed Methods Study, 2019. e-Pub 2019.
Wang J, Talluri R, Shete S. Likelihood-ratio based approach to select X-chromosome inactivation model, 2018. e-Pub 2018.
Wang J, Shete S. Assessing indirect effect in a mediation model with a censored mediator, 2018. e-Pub 2018.
Wang J, Shete S. Estimation of mediating effect in a mediation model with a censored mediator, 2018. e-Pub 2018.
Reyes CC, Wang J, Shelburn SA, Lu C, Gunn BG, Chambers MS, Hanna EY, Yeung SCJ, Shete S. Oral microbiome and oral mucositis, 2018. e-Pub 2018.
Wang J, Shete S. A novel approach to analyze the mediation model when the mediator is a censored variable, 2017. e-Pub 2017.
Wang J, Shete S. Estimating indirect effect when the mediator is a censored variable in a mediation model, 2017. e-Pub 2017.
Simon C, Pandit P, Ferrajoli A, Wang J, Peterson S, Tripp M. Sun Protection and Skin Examination Attitudes and Practices in Patients with Chronic Lymphocytic Leukemia, 2017. e-Pub 2017.
Reyes-Gibby CC, Melkonian SC, Wang J, Yu RK, Shelburne SA, Lu C, Gunn GB, Chambers MS, Hanna EY, Yeung SC, Shete S. Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: an informative gene network analysis, 2017. e-Pub 2017.
Reyes-Gibby CC, Wang J, Shelburne SA, Hutchinson DS, Ajami NJ, Petrosino JF, Lu C, Gunn GB, Chambers MS, Hanna EY, Shete S. Temporal changes in oral microbial composition in head and neck cancer patients at high risk for oral mucositis: a pilot study, 2017. e-Pub 2017.
Heredia N, Strong LL, Forman MR, Christie IC, Wang J, Daniel CR, Zhao H, Bondy ML, Spitz MR, Wilkinson AV. Family social and cultural impacts on Mexican-American adolescents’ body mass index, 2017. e-Pub 2017.
Tripp MK, Wang J, Pandit Talati P, Askins MA, Dellavalle R, Galvan CM, Davies MA, Gershenwald JE, Peterson SK. UV Photography Increases Sun Protection Intentions in Young Adolescents, 2017. e-Pub 2017.
Tripp MK, Wang J, Pandit Talati P, Askins MA, Dellavalle R, Galvan CM, Davies MA, Gershenwald JE, Peterson SK. Sunburn, Sun Protection and Tanning Behavior in Young Adolescents, 2017. e-Pub 2017.
Strong L, Karen-Engquist K, Dominguez E, Wang J, Christie I, Daniel C, Hoover D, McNeill L. Promoting physical activity in dyads of African American and Hispanic women through social networking and mobile technology, 2017. e-Pub 2017.
Wang, J. A unified X-chromosome genetic association test accounting for different XCI processes, 2016. e-Pub 2016.
Wang J, Shete S. Estimation of indirect effect when the mediator is a censored variable, 2016. e-Pub 2016.
Zhu X, Wang J, Peng B, Shete S. Empirical estimation of sequencing error rates using smoothing splines, 2015. e-Pub 2015.
Wang J, Zhu X, Peng B, Shete S. Empirical estimation of sequencing error rates using smoothing splines, 2015. e-Pub 2015.
Wang J, Yu R, Shete S. A unified analysis approach for X-chromosome that accounts for random, skewed and escaping of X-chromosome inactivation, 2014. e-Pub 2014.
Yuan C, Wang J, Shete S, Reyes-Gibby C. Bioinformatics and opioid addiction: gene network analysis, 2014. e-Pub 2014.
Strong L, Wang J, Christie I, Regan S, Franzini L, Wetter D, Reitzel L, McNeill L. Pathways linking neighborhood socioeconomic context to self-rated health in African Americans in Houston, TX, 2013. e-Pub 2013.
Wang J, Yu R, Shete S. X-chromosome genetic association test accounting for X-inactivation, skewed X-inactivation, and escaping of X-inactivation, 2013. e-Pub 2013.
Christie IC, Strong LL, Regan SD, Wang J, Reitzel LR, Wetter DW, McNeill LH. Multiple Factors of Neighborhood Deprivation Differentially Predict Physical Health in a Large African American Sample, 2013. e-Pub 2013.
Wang J, Spitz MR, Amos CI, Wu X, Wetter DW, Cinciripini PM, Shete S. Multiple mediation analysis in case-control studies: application to detecting joint mediating effects of smoking and chronic obstructive pulmonary disease on the association between CHRNA5-A3 genetic locus and lung cancer risk, 2012. e-Pub 2012.
Wang J, Spitz MR, Amos CI, Wu X, Wetter DW, Cinciripini PM, Shete S. Method to analyze multiple mediators in case-control studies with application to detecting mediating effects of smoking and chronic obstructive pulmonary disease on the association between CHRNA5-A3 genetic locus and lung cancer risk, 2012. e-Pub 2012.
Yu RK, Wang J, Shete S. Family-based association test of hypertension among Mexican American, 2012. e-Pub 2012.
Wang J, Yu RK, Shete S. Comparison of multilevel model and the family-based association test (FBAT) for identifying SNPs associated with systolic and diastolic blood pressure using GAW18 simulated data, 2012. e-Pub 2012.
Wang J, Shete S. Selection of top SNPs for genome-wide association study using p values and magnitude of odds ratios, 2011. e-Pub 2011.
Wang J, Shete S. Selection of top SNPs for genome-wide association study using p values and magnitude of odds ratios, 2011. e-Pub 2011.
Wang J, Shete S. Estimation of odds ratio of genetic variants for secondary phenotype associated with primary disease, 2011. e-Pub 2011.
Wang J, Shete S. Estimation of odds ratios of genetic variants for the secondary phenotypes associated with primary diseases, 2010. e-Pub 2010.
Wang J, Spitz MR, Amos CI, Wilkinson AV, Wu X, Shete S. Mediating effects of smoking and chronic obstructive airway disease on the relationship between the CHRNA5-A3 genetic locus and lung cancer risk, 2010. e-Pub 2010.
Wang J, Spitz MR, Amos CI, Wilkinson AV, Wu X, Shete S. Mediating effects of smoking and chronic obstructive airway disease on the relationship between the CHRNA5-A3 genetic locus and lung cancer risk, 2009. e-Pub 2009.
Wang J, Shete S. A test for genetic association that incorporates information from population genetics, 2008. e-Pub 2008.
Strong LL, McNeill LH, Reitzel LR, Li Y, Wang J, Basen-Engquist K. Relationship characteristics and autonomy support for physical activity among inactive women in a dyad-based study. ISPAH Congress 2026.

Book Chapters

Wang J, Shete S. Testing departure from Hardy-Weinberg proportions. In: Statistical Human Genetics. Methods in Molecular Biology. 2nd. Humana Press, 83-115, 2017.
Zhu X, Wang J, Reyes-Gibby C, Shete S. Processing and Analyzing Human Microbiome Data. In: Statistical Human Genetics. Methods in Molecular Biology. 2nd. Humana Press, 649-677, 2017.
Wang J, Shete S. Testing departure from Hardy-Weinberg proportions. In: Methods Mol Biol. Humana Press, 77-102, 2012.

Less

CV information above last modified September 01, 2026

Jian Wang, PhD

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Professional Educational Materials

Abstracts

Book Chapters

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Jian Wang, PhD

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Professional Educational Materials

Abstracts

Book Chapters

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson